NUWE stock forecast, quote, news & analysis
Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems... Show more
Why Nuwellis (NUWE) Stock Is Down -12% in the Last 30 Days
Key Takeaways
- Nuwellis (NUWE) fell roughly 12% over the trailing 30 days on a split-adjusted basis, from about $6.48 on September 30 to $5.68 at the October 30 close.
- The move was punctuated by a 1-for-9 reverse stock split that took effect in late October and by extreme, single-day volume spikes in the week that followed.
- A multicenter pediatric Aquadex study acceptance, conference participation, and an advisory board announcement provided news flow but did not reverse the broader downtrend.
- Operational trends are improving — 26% U.S. revenue growth in the first half of 2026 and 31 Aquadex consoles sold year-to-date — but the company remains unprofitable with a thin cash position.
- The stock's quarterly performance reflects persistent concerns about a small revenue base, ongoing net losses, and potential future dilution.
- For additional detail on this ticker's Price Targets, Earnings, and Forecast, explore the dedicated pages.
- Explore Trending AI Robots to see how automated trading systems are approaching names like this one.
Nuwellis (NUWE) Company Overview and Market Position
Nuwellis, Inc. is a Minnesota-based medical technology company focused on fluid management for patients with cardiorenal conditions. Its flagship product, the Aquadex SmartFlow system, performs controlled ultrafiltration therapy to remove excess fluid from adult and pediatric patients whose fluid overload is unresponsive to medical management, including diuretics. The company targets three clinical markets — pediatrics, critical care, and heart failure — and generates revenue through a razor-and-blades model: console placements followed by recurring sales of single-use disposable blood circuits and catheters.
Formerly known as CHF Solutions, Nuwellis operates in a small but specialized niche and has built a growing pediatric footprint, which accounted for approximately half of U.S. revenue in 2025. Investors follow the stock for its commercial adoption trajectory and recurring-revenue potential, while weighing those positives against a small revenue base, persistent net losses, and Nasdaq listing-compliance considerations.
Nuwellis (NUWE) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, NUWE declined approximately 12% on a split-adjusted basis, moving from a September 30 closing price of about $6.48 to $5.68 at the October 30 close. The path was far from linear: the shares slid through early October, spiked sharply on October 27 on unusually heavy volume, and then settled back below the $6 level.
The broader quarterly picture is more severe. In early August, the stock was trading in the mid-teens on a split-adjusted basis; by late October it was below $6, a decline of roughly 60%. The multi-month slide reflects a steady erosion in investor confidence punctuated by bouts of extreme, low-float volatility rather than a single isolated catalyst.
What Drove NUWE Stock Price in the Last 30 Days
The most consequential development was corporate action rather than operating news. In mid-October, Nuwellis's board approved a one-for-nine reverse stock split, which the company disclosed in an October 22 Form 8-K. The split became effective on October 26, with split-adjusted trading beginning October 27 under a new CUSIP. Reverse splits are commonly used by small-cap companies to lift a sub-dollar share price and support compliance with exchange minimum-bid-price requirements; they are value-neutral for shareholders but often signal underlying financial pressure.
On October 27, the shares surged on trading volume of more than 11 million shares — a dramatic jump from the typical few thousand — coinciding with the announcement that a multicenter pediatric Aquadex study had been accepted for publication in Pediatric Nephrology. That momentum proved short-lived, and the stock gave back much of the gain over the following sessions.
Other news flow during the period was largely operational: participation in several October medical conferences, and a planned pediatric medical and nursing advisory board to advance the Vivian pediatric CRRT system. These items reinforced the company's pediatric-focused growth narrative but did not offset the weight of its financial profile, including a Q2 2026 revenue base of roughly $1.97 million, a narrowed but still substantial net loss, and about $3.9 million in cash.
What Drove NUWE Stock Performance Over the Last Quarter
Over the quarter, the dominant theme was a prolonged decline in a thinly traded micro-cap facing structural challenges. Despite measurable commercial progress — 26% U.S. revenue growth in the first half of 2026 and a console-installation pace described by management as among the strongest in the company's history — the business remains unprofitable and cash-constrained, leaving the equity vulnerable to selling pressure and dilution concerns.
The reverse stock split, authorized by stockholders in July and implemented in late October, capped the period. In combination with low institutional ownership and heavy insider concentration, these factors produced outsized price swings and an overall downward bias that outweighed the company's incremental clinical and commercial announcements.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading systems from a broader universe of hundreds of AI-powered bots that monitor thousands of tickers. Only the top-performing and most relevant bots are highlighted in this section, with each system differing in strategy, trading timeframe, and performance metrics — from short-term momentum approaches to longer-horizon models. The page is designed to help traders and investors discover quantitative tools that may complement their own research. Readers interested in how AI-driven strategies are positioned across the market can explore the available bots to evaluate their methodologies and track records.
NUWE Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape NUWE going forward. Quarterly earnings and any updated guidance will be closely watched, given the company's need to sustain revenue growth while narrowing losses. The planned FDA submission to expand the Aquadex label to pediatric patients weighing 5 kg and above, anticipated by the end of 2026, represents a meaningful regulatory catalyst, as does continued development of the Vivian pediatric CRRT system.
Investors should also monitor recurring circuit utilization from the growing installed base, cash runway and any future capital-raising activity (which could dilute existing holders), and the company's ability to maintain Nasdaq listing compliance after the reverse split. Broader healthcare capital-spending trends and hospital adoption of ultrafiltration therapy remain important macro variables. These are observations, not investment recommendations; outcomes will depend on execution, regulatory timelines, and market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NUWE in upward trend: price may jump up because it broke its lower Bollinger Band on October 23, 2026
NUWE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 44 of 49 cases where NUWE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NUWE's RSI Oscillator exited the oversold zone, 45 of 58 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for NUWE just turned positive on October 27, 2026. Looking at past instances where NUWE's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.
Following a +14.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where NUWE advanced for three days, in 148 of 184 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 16 of 18 cases where NUWE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NUWE as a result. In 78 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NUWE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NUWE entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-7.076) is normal, around the industry mean (4.142). P/E Ratio (0.002) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.007) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. NUWE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NUWE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of heart assist devices
Industry MedicalNursingServices